SCHEDULE: Janus Henderson Amends Tenax Therapeutics Stake

Janus Henderson Group plc has filed an amendment to its Schedule 13G, reporting a 4.0% beneficial ownership stake in Tenax Therapeutics, Inc.

Summary

• Janus Henderson Group plc reported beneficial ownership of 166,666 shares of Tenax Therapeutics, Inc. common stock.
• This represents 4.0% of the class of securities.
• The filing is an Amendment No. 4 to a Schedule 13G.
• Janus Henderson Group plc, a Jersey-based entity, holds shared voting and dispositive power over all 166,666 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• The filing date is August 14, 2025, for an event that occurred on June 30, 2025.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual disclosure of beneficial ownership, providing no positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment adviser and holding company, Janus Henderson Group plc, in a biotechnology company, Tenax Therapeutics, Inc. Such filings are common for institutional investors managing portfolios and reflect their holdings at a specific point in time, rather than strategic industry shifts.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company.

Key Dates

Keywords

Tenax Therapeutics, Janus Henderson Group, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing